Pharmaceutical Benefit Plan Settlements
$71.4 Million available via Pharmaceutical Benefit Plan Settlements
There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices.
The prices were allegedly manipulated as a result of anti-competitive practices undertaken by the drug manufacturers. The number of these opportunities in any given year varies, but there can be several available at the same time.
Immediately Available Settlement(s):
Opana ER Settlement
Date Range: April 2011-September 2018
Settlement Fund: $15 million
Filing Deadline: 1/5/2023
Settlement Overview: A settlement fund has been created to resolve allegations Defendant blocked competition to its drug Opana ER, an opioid pain medication, by entering into a series of anticompetitive agreements which prevented less expensive generic versions becoming available to the class.
Eligible Locations: To be a member of the Settlement Class, you must have indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price of Opana that was purchased in any of the eligible states and territories below:
Arizona*, California, Florida, Hawaii, Iowa, Maine, Massachusetts*, Michigan, Minnesota, Missouri, Mississippi*, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Pennsylvania, Oregon, South Dakota, Tennessee, Utah, Vermont, West Virginia, Wisconsin, and the District of Columbia.
* With respect to Arizona, Massachusetts, and Mississippi, Class Members must have purchased, paid for, and/or provided reimbursement for some or all of the purchase price of brand or generic Opana ER from June 4, 2011, through September 2018.
Eligible Drug: Brand or generic Opana ER, in the 5, 10, 20, 30, or 40 mg strengths, sold by Endo or Impax
Date Range: April 2010-December 2017
Settlement Fund: $56,438,000
Filing Deadline: 2/3/2023
Settlement Overview: A settlement fund has been created to resolve allegations Defendants committed an unlawful scheme to maintain their monopoly in the market for Namenda (treatment for Alzheimer's Disease) by blocking the generic competition to Namenda through pay-for-delay agreements.
Eligible Locations: To be a member of the Settlement Class, you must have indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price of branded Namenda IR 5 or 10 mg tablets, their AB-rated generic equivalents, and/or branded Namenda XR capsules, other than for resale, in the United States and its territories.
Eligible Drug: Branded Namenda IR 5 or 10 mg tablets, their AB-rated generic equivalents, and branded Namenda XR capsules.
Recommended Next Steps Data is often required to complete your claim for settlements in this category. Connect us with a member of your Benefits Department so an MCAG representative can describe the information that is necessary to complete your claim for these pharmaceutical settlements. We typically only need a 5 to 10 minute call. We will quickly review the process so we can efficiently obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements.
Eligible contracted clients can expect to be contacted by an MCAG representative to review and assist with gathering the necessary information for these settlements.
MCAG is not the Settlement/Class Administrator, and this is not an official settlement website.
Need more information? CLICK HERE to complete our contact form and an MCAG representative will respond shortly.